Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $57

Benzinga Newsdesk www.benzinga.com Positive 81.5%

Neg 0% Neu 0% Pos 81.5%

Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $53 to $57.